Epredia’s E1000 Dx Digital Pathology Solution Wins 2025 International Scanner Benchmark Awards from the Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA)

September 29, 2025

RUNCORN, United Kingdom--(BUSINESS WIRE)--The Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA), an international organization that advances the use of validated AI solutions in clinical practice, has announced that Epredia, a global leader in precision cancer diagnostics, has won three categories in the 2025 International Scanner Benchmark (ISB) for Epredia’s E1000 Dx Digital Pathology Solution. The ISB recognizes excellence in quality, throughput, and design of digital slide scanning technology for pathology.

The E1000 Dx consists of a high-speed, automated, whole-slide imaging digital scanner with medical grade viewer and advanced image management and viewer software that creates high-resolution digital images of up to 1,500 tissue samples daily. The E1000 Dx is designed to maximize laboratory throughput and efficiency with technology advancements in sample detection and quality control procedures, which has the potential to make diagnostics more efficient and accurate.

EMPAIA supports regulatory, legal, technical, and organizational pathways to the adoption of validated and certified AI solutions. Through the ISB, EMPAIA seeks to identify the pathology industry’s top image-based diagnostics technologies, which provide detailed digital images that are critical inputs for potential future AI-powered diagnostics.

Epredia’s E1000 Dx won the 2025 ISB in the categories of Quality for digital images at 20x magnification, and Quality and High Throughput for digital images at 40x magnification, the highest level of magnification tested. The honors were based on a comprehensive and objective scanner evaluation, performed on samples from a variety of laboratories across Europe and reviewed by a panel of pathologists. Winners were awarded at the 37th European Congress of Pathology in Vienna, Austria, in September.

Epredia’s E1000 Dx builds on technology originally developed by 3DHISTECH, a leading pathology and diagnostics company and close commercial partner of Epredia. 3DHISTECH also received top honors in the ISB for its Pannoramic 480 Dx digital slide scanner, in the categories of High Throughput for digital images at 20x magnification and Technical capabilities, as well as being recognized with the prestigious Innovator 2025 Award. Epredia is a distributor of the full 3DHISTECH digital pathology portfolio including the Pannoramic 480 Dx.

Steven Lynum, President of Epredia, said, "Digital pathology is the future of cancer diagnostics. As pathology laboratories face greater pressure to speed up processes and reduce costs, we are deeply honored that EMPAIA has recognized the E1000 Dx as a leader in both high throughput and quality. AI holds tremendous potential to enhance the way conditions like cancer are diagnosed and ultimately treated, but AI is only as powerful as the images available to analyze. We look forward to Epredia and 3DHISTECH solutions helping laboratories maximize their digital pathology investment today as well as the potential of this technology to support AI-powered diagnostics in the future."

---

A propos d'Epredia

Epredia est un leader mondial dans le domaine de l'anatomopathologie.

Epredia est un leader mondial dans le domaine de la pathologie anatomique, fournissant des solutions complètes pour le diagnostic de précision du cancer et le diagnostic des tissus. S'appuyant sur des marques clés telles que Erie Scientific, Menzel-Gläser, Microm, Shandon et Richard-Allan Scientific, le portefeuille d'Epredia comprend des lames de microscope, des instruments et des consommables. Epredia a été créée à la suite de l'acquisition de l'activité de pathologie anatomique de Thermo Fisher Scientific par PHC Holdings en 2019. Epredia est présente sur des sites importants aux États-Unis, au Royaume-Uni, en Allemagne, en Suisse et en Chine, avec un total d'environ 1 200 employés. Epredia s'engage à réaliser sa mission d'améliorer les vies en améliorant les diagnostics de cancer pour les patients du monde entier. Pour plus d'informations sur Epredia et ses produits, veuillez consulter www.epredia.com.

La société Epredia a pour mission d'améliorer les vies en améliorant les diagnostics du cancer pour les patients du monde entier.

A propos de PHC Holdings Corporation (Groupe PHC)

La société PHC Holdings Corporation (Groupe PHC)

PHC Holdings Corporation (TSE 6523) est une entreprise mondiale de soins de santé dont la mission est de contribuer à la santé de la société par le biais de solutions de soins de santé qui ont un impact positif et améliorent la vie des gens. Ses filiales (appelées collectivement PHC Group) comprennent PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford et Wemex. Ensemble, ces entreprises développent, fabriquent, vendent et entretiennent des solutions dans les domaines de la gestion du diabète, des solutions de soins de santé, des sciences de la vie et du diagnostic. Les ventes nettes consolidées de PHC Group’étaient de 356,4 milliards de yens pour l’exercice 2022, avec une distribution mondiale de produits et de services dans plus de 125 pays.
www.phchd.com

Pour plus d'informations, veuillez contacter :

Julia Cottran, directrice générale de l'entreprise.
Julia Cottrill
Communication d'entreprise du groupe HPC
Email : julia.cottrill@phchd.com

Julia Cottrill
GroupePHC Communications
Courriel